Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients

Benzinga · 3d ago

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the signing of an MOU in Seoul, South Korea, with Samsung Medical Center (SMC), regarding a potential clinical trial in pancreatic cancer patients. Any such trial would be subject to regulatory and ethics committee approvals.